Clinical Trials

Inclusion Criteria:

• Age 18-80 years, male, female, any race/ethnicity.
• Diagnosis of bipolar I disorder or bipolar II disorder, or bipolar (BP) schizoaffective defined by DSM-IV or DSM-V criteria, SCID- confirmed. If patient has already completed a DSM-IV or DSM-V SCID within one year of enrollment, they will not be required to repeat the SCID assessment.
• Ability for a referring clinician or research clinician to complete a retrospective clinical assessment of response to lithium, mood stabilizing anticonvulsants(carbamazepine, oxcarbamazepine, divalproex sodium, lamotrigine, zonisamide) typical and atypical antipsychotics, stimulants and related compounds (modafinil / armodafinil) and, unimodal antidepressants utilizing the Alda scale.

Exclusion Criteria: 

• Inability to understand English.
• Inability or unwillingness to provide informed consent or scoring less than 80% on the comprehension assessment (CA) form.
• Unwilling to consent to providing bio-specimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design.
• Actively psychotic (i.e., impaired judgment, false fixed beliefs which are delusions or hallucinations) or active suicidal behavior (including active suicidal ideation or planning).
• A score of 20 or higher on the YMRS, OR a score of 6 or higher on question #8 of the YMRS.
• Immunocompromised patients who have received a blood transfusion within the past 6 weeks.
• Involuntary patients.

Eligibility last updated 9/25/23. Questions regarding updates should be directed to the study team contact.